45 results about "Cannabinoid receptor ligand" patented technology

Disclosed herein are cannabinoid receptor ligands of formula (I)wherein Y, X1, X2, X3, R1, and R2 are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Disclosed herein are cannabinoid receptor ligands of formula (I)wherein Ring A and R1 are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also described.

The present invention relates to thiazolidinylidene containing compounds of formula (I)wherein R1, R2, R3, R4, R5, R6, and X are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Disclosed herein are cannabinoid receptor ligands of formula (I)wherein A1 and Rx are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

The present invention relates to compounds of formula (I)wherein A, E, L2, R1, R3, R4 and R5 are as defined in the herein, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Cannabinoid receptor ligands of formula (I)wherein Ring A and R1 are as defined in the specification. Compositions including such compounds, and methods of treating conditions and disorders using such compounds and compositions are also described.

The present invention provides novel compounds of Formula (I)which are CB2 selective ligands useful for the treatment of pain.

The present invention relates to non-classical cannabinoids that are ligands of the peripheral cannabinoid receptor CB2, and to pharmaceutical compositions thereof comprising as an active ingredient novel (+) alpha-pinene derivatives, which are useful for prevention and treatment of autoimmune diseases including but not limited to rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, diabetes mellitus type I, hepatitis, psoriasis, tissue rejection in organ transplants, malabsorption syndromes such as celiac disease, pulmonary diseases such as asthma and Sjögren's syndrome, inflammation including inflammatory bowel disease, pain including peripheral, visceral, neurophathic inflammatory and referred pain, muscle spasticity, cardiovascular disorders including arrhythmia, hypertension and myocardial ischemia, neurological disorders including stroke, migraine and cluster headaches, neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's chorea, prion-associated neurodegeneration, CNS poisoning and certain types of cancer.

The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and / or disorders modulated by a cannabinoid receptor.

Disclosed herein are cannabinoid receptor ligands of formula (I)wherein L1, A1, R1g, z, R2, R3, and R4 are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and / or disorders modulated by a cannabinoid receptor (such as pain, neurodegenerative disorders, eating disorders, weight loss or control, and obesity).

The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and / or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).

The present invention relates to atypical cannabinoids, i.e. ligands of the peripheral cannabinoid receptor CB2, and pharmaceutical compositions thereof comprising novel (+) α-pinene derivatives as active ingredients, which are useful in the prophylaxis of and treatment of autoimmune diseases including but not limited to rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, type I diabetes, hepatitis, psoriasis and immune Associated disorders, including but not limited to tissue rejection in organ transplantation, malabsorption syndromes such as celiac disease, pulmonary diseases such as asthma and Sjögren's syndrome, inflammation including inflammatory bowel disease, including peripheral, visceral, neurological Sexual, inflammatory and associated pain, muscle spasms, cardiovascular disorders including arrhythmia, hypertension and myocardial ischemia, nervous system disorders including stroke, migraine and cluster headaches, including Parkinson's disease, Neurodegenerative diseases like Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, prion-related neurodegeneration, CNS poisoning, and certain types of cancer.